000			04207cam a2200457 i 4500
001			on1330713484
003			OCoLC
005			20240726104901.0
008			220617s2022 quc ob 001 0 eng
040			_aNLC _beng _erda _cNLC _dOCLCF _dNLC _dLGG _dEBLCP _dNT _dYDX _dUKAHL
015			_a20220272387 _2can
020			_a9780228013501 _q((electronic)l(electronic)ctronic)PUB
020			_a9780228013495 _q((electronic)l(electronic)ctronic)
043			_ae-uk---
050	0	4	_aRM666 _b.R464 2022
049			_aMAIN
100	1		_aTaylor, Suzanne _c(Research fellow), _e1
245	1	0	_aRemedicalizing cannabis : _bscience, industry, and drug policy / _cSuzanne Taylor.
260			_aMontreal ; _aKingston ; _aLondon ; _aChicago : _bMcGill-Queen's University Press, _c(c)2022.
300			_a1 online resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_adata file _2rda
490	1		_aIntoxicating histories ; _v3
504			_a2
505	0	0	_aUnderstanding Cannabis: Pharmacology, Laboratory Research, and Drug Control, 1964-82 -- _tCannabis in the Clinic: Clinical Pharmacology and the Therapeutic Applications of Cannabis, 1973-82 -- _tEvidence-Based Policy? The Development of Expert Committees, 1972-82 -- _tIndustrializing Cannabis: The Pharmaceutical Industry and the Remedicalization of Cannabis, 1973-2001 -- _tForces of Necessity: Lay Advocacy and the Remedicalization of Cannabis, 1973-2001 -- _tEstablishing Therapeutic Cannabis: The Role of Expert Advice, 1997-2001 -- _tFrom Anecdotal to Evidence-Based Medicine: The Role of Clinical Trials, 1995-2005 -- _tAccessing Cannabis-Based Medicinal Products (CBMPS), 2009-21.
520	0		_a"When cannabis tincture was withdrawn as a medical product in the UK in 1973, cannabis became regulated solely as an illicit drug. Within a decade cannabis-based drugs were back in the clinic. The UK is one of the biggest producers of medicinal cannabis, but few patients have access to these medicines. High-profile cases of parents campaigning for access to cannabis oil for severe and rare forms of epilepsy in their children are the most recent in a long line of controversies over cannabis and cannabis-based medicines. With mounting questions about patient access, the effectiveness of international drug control systems, and the role of expert advice, it is crucial to understand how we have arrived at this situation. While the historical literature has focused on cannabis as an illicit substance, Remedicalising Cannabis considers the botanical product and its potential to yield medical applications. Investigating the remedicalization of cannabis, Taylor explores the process whereby boundaries shift between illicit drug and licit medicine. Basing her arguments on archival material from expert committees, researchers, and activists and in-depth interviews with key players, Suzanne Taylor traces the issues and interests involved in this process, demonstrating the important roles of changing scientific knowledge, expert advice, industry, clinical trials, and patient activism. Remedicalising Cannabis investigates the evolving tensions that have brought us to the current situation and demonstrates the role of history in understanding today's debates about cannabis."-- _cProvided by publisher.
530			_a2 _ub
650		0	_aCannabis _xTherapeutic use _zGreat Britain _xHistory _y20th century.
650		0	_aCannabis _xGovernment policy _zGreat Britain _xHistory _y20th century.
650		0	_aMarijuana industry _zGreat Britain _xHistory _y20th century.
650		0	_aCannabis _xTherapeutic use _zGreat Britain _xHistory _y21st century.
650		0	_aCannabis _xGovernment policy _zGreat Britain _xHistory _y21st century.
650		0	_aMarijuana industry _zGreat Britain _xHistory _y21st century.
655		1	_aElectronic Books.
856	4	0	_zClick to access digital title | log in using your CIU ID number and my.ciu.edu password. _uhttpss://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=3546736&site=eds-live&custid=s3260518
942			_cOB _D _eEB _hRM. _m2022 _QOL _R _x _8NFIC _2LOC
994			_a92 _bNT
999			_c81596 _d81596
902			_a1 _bCynthia Snell _c1 _dCynthia Snell